Written by authors from the world’s most prominent cancer centers, Chronic Lymphocytic Leukemia supplies a comprehensive, up-to-date picture of CLL and how to better treat patients inflicted with the disease.
New information on developments in the molecular pathogenesis of this disease impacts how physicians approach and treat patients with CLL. The various predisposing factors for the disease are addressed along with current and future treatment modalities and recommended standards of care.
Key features include:
- introduction by Kanti Rai, MD who developed the Rai Classification and Staging system used in CLL diagnosis
- CLL in relationship to gene expression profiling and molecular abnormalities
- familial clustering and gene predisposition
- targeted therapy trials
- clinical patient management based upon stage and progression of disease
Table of Contents
1. Origin and Nature of the CLL Cell. 2. Gene Expression Profiling. 3. Molecular Pathogenesis. 4. CLL and the B Cell Receptor. 5. Epidemiology and Familial CLL. 6. Apoptosis Disregulation in CLL. 7. Differential Diagnosis, Staging, and Prognostic Factors. 8. Frontline Therapy. 9. Treatment of Relapsed Disease. 10. New Therapies. 11. Transplant in CLL. 12. Gene therapy, vaccines and immune modulation. 13. PLL. 14. CLL Specific Complications: Autoimmunity and Richter’s Syndrome. 15. Infections in CLL.
SUSAN O’BRIEN is Professor of Medicine and Clinical Consultant and Special Assistant to the Physician-in-Chief, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She received her M.D. from the University of Medicine and Dentistry of New Jersey Medical School, Newark, New Jersey, USA. In recognition of her contributions to the medical field, Dr. O’Brien has been named on the lists of "America’s Top Physicians" and "The Best Doctors in America." She is an experienced writer of and contributor to numerous books, journals, manuals, teaching aids, and other publications, and a frequent invited speaker at conferences, seminars, and conventions. Dr. O’Brien is a member of numerous professional organizations, and she currently serves as Chair of the National Comprehensive Cancer Network’s Chronic Myelogenous Leukemia Guidelines Panel. To fund her research in leukemia, she has received grants and funding from Ortho-McNeil and Berlex, Inc., among others.
JOHN G. GRIBBEN is Professor of Experimental Cancer Medicine and Director of Stem Cell Transplantation, Barts and the London School of Medicine, and Medical Director of the North East London Cancer Research Network, London, UK. He received his M.D. from the University of Glasgow, Glasgow, UK. Professor Gribben leads the newly established Centre for Experimental Cancer Medicine, which facilitates translational cancer research from "basic scientific discovery" to "novel approaches to care of patients with cancer." Dr. Gribben is a founding member of the Chronic Lymphocytic Leukemia Consortium and is also a current member or fellow of several professional organizations, including the American Society for Clinical Investigation and the Academy of Medical Sciences. Dr. Gribben is the author of more than 300 articles and chapters on the subjects of stem cell transportation for cancer treatment, tumor antigens and B cell malignancies, and leukemia and lymphoma.